Although they used siRNA and shRNA rather than medication treatment, Sukhanova et al. demonstrated that SC4MOL inactivation sensitized A431, SCC61, SCC68, and PC9 tumor cells to erlotinib, an EGFR kinase inhibitor [130]. The gene discussed is MSMO1; the disease is neoplasm.